U.S. FDA issues four observations to Gland Pharma formulation facility near Hyderabad
The four Form 483 observations followed an unannounced inspection on current good manufacturing practice at the facility in Dundigal between October 12 and 23
· 10/24/2026, 5:36:56 AM· 2 min read
The four Form 483 observations followed an unannounced inspection on current good manufacturing practice at the facility in Dundigal between October 12 and 23
Read original story →Related stories
breaking
Low pressure over Bay of Bengal likely to turn into cyclonic storm, landfall expected on Oct. 28
breaking
Contract renewals of teachers linked to MDMA case: Vigilance inquiry underway against former SSK official
breaking
Andhra CM alerts officials about the cyclone in Bay of Bengal
breaking